Fampridine for gait imbalance in patients with multiple sclerosis (MS): a systematic review and meta-analysis

Ghorbanpour, Sahar; Rahimibarghani, Sarvenaz; Rohani, Setareh; Rastkar, Mohsen; Ghajarzadeh, Mahsa

doi:10.1007/s10072-023-06795-9

Cited by 6 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To the best of our knowledge, no previous studies have explored the effect of fampridine on inflammation in pwMS. Although we have no data on physical activity, previous studies have demonstrated that fampridine improves gait function [27] and that physical activity can alter the level of inflammatory cytokines [11]. Our results suggest that fampridine does not influence the quantity of physical activity to such a degree that it affects the levels of inflammatory markers in the blood of pwMS following 14 days of treatment.…”

Section: Discussionmentioning

confidence: 46%

Performance Measures and Plasma Biomarker Levels in Patients with Multiple Sclerosis after 14 Days of Fampridine Treatment: An Explorative Study

Thorning,

Lambertsen,

Jensen

et al. 2024

IJMS

View full text Add to dashboard Cite

Peripheral cytokine levels may serve as biomarkers for treatment response and disease monitoring in patients with multiple sclerosis (pwMS). The objectives were to assess changes in plasma biomarkers in PwMS after 14 days of fampridine treatment and to explore correlations between changes in performance measures and plasma biomarkers. We included 27 PwMS, 14 women and 13 men, aged 52.0 ± 11.6 years, with a disease duration of 17 ± 8.5 years, and an Expanded Disability Status Scale of 6 [IQR 5.0/6.5]. Gait and hand function were assessed using performance tests completed prior to fampridine and after 14 days of treatment. Venous blood was obtained, and chemiluminescence analysis conducted to assess plasma cytokines and neurodegenerative markers. All performance measures demonstrated improvements. Biomarkers showed decreased tumor necrosis factor (TNF) receptor-2 levels. Associations were found between change scores in (i) Six Spot Step Test and Interleukin (IL)-2, IL-8, and IL-17 levels; (ii) timed 25-foot walk and interferon-γ, IL-2, IL-8, TNF-α, and neurofilament light levels, and (iii) 12-Item Multiple Sclerosis Walking Scale and IL-17 levels. The associations may reflect increased MS-related inflammatory activity rather than a fampridine-induced response or that a higher level of inflammation induces a better response to fampridine.

show abstract

Section: Discussionmentioning

confidence: 46%

Performance Measures and Plasma Biomarker Levels in Patients with Multiple Sclerosis after 14 Days of Fampridine Treatment: An Explorative Study

Thorning,

Lambertsen,

Jensen

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…The MS symptoms ( Jakimovski et al, 2024 ) differ according to individuals ( Ghorbanpour et al, 2023 ), but the most common are muscle weakness, muscle hyperactivity or spasticity; sensory symptoms (paraesthesia); visual symptoms; sphincter, sexual, cognitive, and psychiatric disorders; severe fatigue; pain; and walking disorders ( Ghorbanpour et al, 2023 ; Jakimovski et al, 2024 ). A thorough assessment of gait is essential, since among the symptoms mentioned above, people with MS (PwMS) report that walking is the most affected function and that it should be treated as a priority ( Ghorbanpour et al, 2023 ). Commonly, walking disorders can be treated with physiotherapy ( Etoom et al, 2018 ) or drug-based medication ( Goodman et al, 2015 ).…”

Section: Introductionmentioning

confidence: 99%

Neuro-orthopaedic check-up and walking in people with multiple sclerosis: toward a more specific assessment to improve rehabilitation results

Sagawa,

Guilhendou,

Moulin

et al. 2024

J Exerc Rehabil

View full text Add to dashboard Cite

The rehabilitation process of people with multiple sclerosis (PwMS) is a challenge, and decision-making requires a thorough assessment to increase the chances of success in rehabilitation planning. The aim of this study was to investigate the importance of the neuro-orthopaedic check-Up (NOChU) for gait prognosis. Participated in the study 105 PwMS with different levels of impairment. The NOChU includes measurements of passive range of motion (ROM), muscle strength, and spasticity. Additionally, was carried out the spatial-temporal analysis of the walking, Timed Up and Go test, and 6-min walk test. ROM remained relatively preserved to perform daily life activities except for ankle dorsiflexion. Muscle strength was also relatively preserved. Spasticity affected especially the ankle muscles, clearly the sural triceps. Among the NOChU measurements the catch seemed to have the most impact on walking on its different phases and on other activities. Accurate NOChU measurements play a crucial role in clinical settings, guiding informed decisions in rehabilitation planning. Future research endeavours could focus on exploring the correlations between NOChU deficiencies and the decline in walking capabilities among PwMS, with the goal of proposing personalized treatment strategies that address their specific requirements.

show abstract

Dalfampridine in the treatment of primary fatigue in patients with multiple sclerosis: a randomized clinical trail

Mavandadi,

Paybast,

Mirzadeh

et al. 2024

Acta Neurol Belg

View full text Add to dashboard Cite

Fampridine for gait imbalance in patients with multiple sclerosis (MS): a systematic review and meta-analysis

Cited by 6 publications

References 31 publications

Performance Measures and Plasma Biomarker Levels in Patients with Multiple Sclerosis after 14 Days of Fampridine Treatment: An Explorative Study

Performance Measures and Plasma Biomarker Levels in Patients with Multiple Sclerosis after 14 Days of Fampridine Treatment: An Explorative Study

Neuro-orthopaedic check-up and walking in people with multiple sclerosis: toward a more specific assessment to improve rehabilitation results

Dalfampridine in the treatment of primary fatigue in patients with multiple sclerosis: a randomized clinical trail

Contact Info

Product

Resources

About